Clinical Trial Update: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating mirvetuximab soravtansine with carboplatin for FRα-expressing, platinum-sensitive epithelial ovarian cancer in second-line tre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: AbbVie | Conditions: High Grade Ovarian Cancer, Primary Peritoneal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING